Botanix Pharmaceuticals (BOT) Investor Presentation summary

Commercial launch and sales performance

• Sofdra commercial launch began in February 2025, with digital rollout in March, driving strong new patient and prescriber growth and high refill rates exceeding industry standards.

• New patient arrivals are trending at over 2,000 per month within 9 weeks of launch, with refill rates close to 100% month-on-month.

• Individual prescribers exceeded 1,000 per month, and gross monthly revenue more than doubled from February to March 2025.

• Positive patient and prescriber feedback highlights efficacy, ease of use, and seamless pharmacy experience.

• The platform's direct-to-patient model increases profitability, patient compliance, and reduces distribution costs.

Market opportunity and product positioning

• Sofdra is the first and only new chemical entity for primary axillary hyperhidrosis, targeting a US market of ~10 million patients, with 3.7 million actively seeking treatment.

• The product offers a unique mechanism of action, selectively blocking M3 receptors in sweat glands to reduce sweating.

• High patient need is demonstrated by significant quality-of-life impact and willingness to pay for effective treatment.

• Sofdra is positioned as a superior alternative to existing treatments, including antiperspirants, oral drugs, and invasive procedures.

Growth strategy and capital raising

• A$40 million capital raise is underway to accelerate US commercialisation, expand the sales force, enhance digital marketing, increase inventory, and support platform expansion.

• Proceeds will also fund operating expenses, medical meetings, and transaction costs, with a pro forma cash balance of ~A$68 million post-raise.

• Sales team expansion is being accelerated ahead of plan due to strong demand and sales performance.

• Increased investment is planned in digital channels, manufacturing, inventory, and pharmacy capacity.